Predicting Treatment of Bioprosthetic Aortic Valve Failure in the United States: A Proposed Model
Philippe Généreux, Martin B. Leon, Roy D. Dar, Rishi Puri, Yoseph Rozenman, Molly Szerlip, Pradeep Yadav, Vinod H. Thourani, Philippe Pîbarot, Danny Dvir
Abstract
•Transcatheter aortic valve replacement (TAVR) is the dominant treatment for aortic stenosis; the need to treat TAVR failure is increasing.•TAVR valve-in-valve (ViV) is predicted to reach ∼42,000 procedures by 2035.•TAVR ViV will represent ∼15% of all TAVR performed by 2035.•TAVR-in-TAVR will match TAVR-in-surgical aortic valve replacement by 2028 and dominate thereafter.•To ensure the viability of TAVR ViV, the use of leaflet modification is needed.
Topics & Concepts
CardiologyInternal medicineMedicineCardiac Valve Diseases and TreatmentsInfective Endocarditis Diagnosis and ManagementCardiac, Anesthesia and Surgical Outcomes